Merck & Co., Inc. (MRK)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
73.61+0.56 (+0.77%)
At close: 4:02PM EDT
73.62 +0.01 (0.01%)
After hours: 07:57PM EDT
After hours: 07:57PM EDT
| Previous close | 73.05 |
| Open | 73.59 |
| Bid | 73.62 x 1100 |
| Ask | 73.73 x 1100 |
| Day's range | 73.35 - 74.63 |
| 52-week range | 68.44 - 81.68 |
| Volume | 14,559,829 |
| Avg. volume | 10,420,806 |
| Market cap | 186.334B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 33.52 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.60 (3.56%) |
| Ex-dividend date | 14 Sept 2021 |
| 1y target est | N/A |
- Business Wire
LYNPARZA® (olaparib) in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)
KENILWORTH, N.J., September 24, 2021--LYNPARZA in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial
- Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
KENILWORTH, N.J., September 19, 2021--KEYTRUDA Plus Chemo Reduced Risk of Death by 27% Versus Chemo as 1L Treatment for Patients With Metastatic TNBC Whose Tumors Expressed PD L1 (CPS ≥10)
- Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting
KENILWORTH, N.J., September 18, 2021--Merck’s KEYTRUDA Demonstrated Superior Recurrence-Free Survival in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo
© 2021 Verizon Media. All rights reserved.
